T. Rowe Price Investment Management
RNAM

T. Rowe Price Investment Management’s Avidity Biosciences RNAM Stock Holding History

T. Rowe Price Investment Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,401,906
Closed -$61.1M – 949
2025
Q3 		$61.1M Buy
1,401,906
+588,001
+72% +$23.8M 0.04% 351
2025
Q2 		$23.1M Buy
813,905
+42,747
+6% +$1.27M 0.01% 485
2025
Q1 		$22.8M Buy
+771,158
New +$24M 0.02% 500
2023
Q2 		– Sell
-397,970
Closed -$6.11M – 585
2023
Q1 		$6.11M Hold
397,970
– – ﹤0.01% 530
2022
Q4 		$8.83M Sell
397,970
-2,377,322
-86% -$35.4M 0.01% 510
2022
Q3 		$45.3M Buy
+2,775,292
New +$53.1M 0.04% 360

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Investment Management's RNAM Position: Q4 2025 in Review

T. Rowe Price Investment Management sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 1,401,906 shares — an estimated $61.1M sold.

T. Rowe Price Investment Management first reported a position in RNAM in Q3 2022 and held it in 6 quarters. The position peaked at $61.1M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • T. Rowe Price Investment Management reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,401,906 Avidity Biosciences shares in Q4 2025, an estimated $61.1M.
  • T. Rowe Price Investment Management first reported a position in Avidity Biosciences in Q3 2022 and held it in 6 quarters.
  • T. Rowe Price Investment Management's Avidity Biosciences position peaked at $61.1M in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.